|
|
Post by digger on May 13, 2018 6:16:09 GMT -5
tcoyd.org/2018/04/the-newest-fast-acting-insulins-how-fast-is-fast/"So can these new “ultra-rapid acting insulins” get us away from the pre-bolus and enable us to take insulin when we actually eat? I’m sorry to say, but I just don’t think so. Not yet. I should clarify that I’m NOT talking about Afrezza which you actually CAN (and should) take when you start eating… or even after eating because it is that fast." But then he confuses the issue when he says: "Ultimately I think having a truly fast-acting insulin that you can inject or put into a pump is the single biggest need for insulin therapy in T1D. So for that reason, I’m super super glad to see companies working on this." So why does he think the single biggest need is an injectable ultrafast insulin when there is an inhalable one?
|
|
|
|
Post by cjm18 on May 13, 2018 7:09:49 GMT -5
Or why does he think Speed matters. And admit Afrezza is the fastest and fiasp is still slow.
|
|
|
|
Post by barnstormer on May 13, 2018 7:28:03 GMT -5
My experience when attending a TCOYD meeting in La Jolla as a MNKD shareholder and not a diabetic is that TYCOYD tries not to really endorse any particular insulin. The organization is sponsored by several of the insulin makers so they stay away from favoring one over the other. Edelman actually pulled out his Afrezza and demonstrated it at one of the meetings, but wasn't lavish with praise as not to offend NOVO who picked up the ticket for the meal. Pettus has just joined Kendall's advisory team so he might be a little more forthcoming with praise outside the TYCOD platform.
|
|
|
|
Post by digger on May 13, 2018 9:42:53 GMT -5
My experience when attending a TCOYD meeting in La Jolla as a MNKD shareholder and not a diabetic is that TYCOYD tries not to really endorse any particular insulin. The organization is sponsored by several of the insulin makers so they stay away from favoring one over the other. Edelman actually pulled out his Afrezza and demonstrated it at one of the meetings, but wasn't lavish with praise as not to offend NOVO who picked up the ticket for the meal. Pettus has just joined Kendall's advisory team so he might be a little more forthcoming with praise outside the TYCOD platform. Yeah, but like "cjm" above, why does he think there needs to be, in particular, a faster injectable? For pumps maybe? Also, does he not think that afrezza can replace injectables? Kind of leaves you hanging. |
|
|
|
Post by goyocafe on May 13, 2018 10:18:34 GMT -5
My experience when attending a TCOYD meeting in La Jolla as a MNKD shareholder and not a diabetic is that TYCOYD tries not to really endorse any particular insulin. The organization is sponsored by several of the insulin makers so they stay away from favoring one over the other. Edelman actually pulled out his Afrezza and demonstrated it at one of the meetings, but wasn't lavish with praise as not to offend NOVO who picked up the ticket for the meal. Pettus has just joined Kendall's advisory team so he might be a little more forthcoming with praise outside the TYCOD platform. Yeah, but like "cjm" above, why does he think there needs to be, in particular, a faster injectable? For pumps maybe? Also, does he not think that afrezza can replace injectables? Kind of leaves you hanging. Agedhippie indicated a week or so ago that diabetics want the least possible inconvenience when dealing with the disease. If there were an injectable insulin with the same PK/PD profile as Afrezza, the Artificial Pancreas would win hands down in that category. Unfortunately, subcutaneous delivery of insulin is inherently slow, and Fiasp is the best anyone has come up with despite a lot of effort and money going into it. |
|
|
|
Post by joeypotsandpans on May 13, 2018 11:39:54 GMT -5
I like this from the comments section  James M. Passero 3:51 pm on May 7, 2018 I am curious as to why you are not talking about Afrezza. It is proven to be faster than Fiasp and easier to use. Could you please explain why you are not promoting Afrezza. I heard Dr. Edelman say in a presentation that he is in fact using Afrezza himself. To me, that speaks volumes about the efficacy of Afrezza. Thank you in advance for your response. Reply TCOYD 9:04 am on May 8, 2018 This article is focused on the latest fast-acting insulin to hit the market. If you’d like info and opinions on Afrezza specifically, please watch Dr. Pettus and Dr. Edelman speak about them in these videos: www.youtube.com/watch?v=qAwrjX0928Ywww.youtube.com/watch?v=Xtg1ESeqAQw&t=84sReply |
|
|
|
Post by peppy on May 13, 2018 15:35:34 GMT -5
Lying has become the American way of life. Fiasp is the latest, old and lousy Rapid Acting Analog Insulin. (It burns) Your blood glucoses still rise after eating, and Fiasp still brings blood glucose down slowly. Afrezza in the other hand, phase one insulin reaction, keeps your blood glucose from going high in the first place. Fiasp may be the latest insulin, however it is not the better insulin. Do you think the author would tolerate this reply?   |
|
|
|
Post by digger on May 13, 2018 16:07:02 GMT -5
I like this from the comments section James M. Passero 3:51 pm on May 7, 2018 I am curious as to why you are not talking about Afrezza. It is proven to be faster than Fiasp and easier to use. Could you please explain why you are not promoting Afrezza. I heard Dr. Edelman say in a presentation that he is in fact using Afrezza himself. To me, that speaks volumes about the efficacy of Afrezza. Thank you in advance for your response. Reply TCOYD 9:04 am on May 8, 2018 This article is focused on the latest fast-acting insulin to hit the market. If you’d like info and opinions on Afrezza specifically, please watch Dr. Pettus and Dr. Edelman speak about them in these videos: www.youtube.com/watch?v=qAwrjX0928Ywww.youtube.com/watch?v=Xtg1ESeqAQw&t=84sReply And I noticed one of the other comments -- "I have been using Fiasp since it became available in Canada. I find that it works well for me." Why isn't afrezza already approved in Canada? I can't imagine it'd be that much more difficult or expensive than Brazil or India. |
|
|
|
Post by sayhey24 on May 14, 2018 5:25:30 GMT -5
My experience when attending a TCOYD meeting in La Jolla as a MNKD shareholder and not a diabetic is that TYCOYD tries not to really endorse any particular insulin. The organization is sponsored by several of the insulin makers so they stay away from favoring one over the other. Edelman actually pulled out his Afrezza and demonstrated it at one of the meetings, but wasn't lavish with praise as not to offend NOVO who picked up the ticket for the meal. Pettus has just joined Kendall's advisory team so he might be a little more forthcoming with praise outside the TYCOD platform. Yeah, but like "cjm" above, why does he think there needs to be, in particular, a faster injectable? For pumps maybe? Also, does he not think that afrezza can replace injectables? Kind of leaves you hanging. For the same reason Al said he needed a faster insulin. Without it the Pump will never be the AP. For the T1s you still need the basal. Al saw the patch pump fitting this need. Also, for the 20% of T1s who have COPD, etc and can't take afrezza you still need the injectable. For the T2, its a different story. Just use the afrezza as the standard of care day 1, even as a prediabetic and get the load off the beta cells. |
|
|
|
Post by akemp3000 on May 14, 2018 7:29:36 GMT -5
Once the STAT study results are released and Dr. Kendall can share with his peers how fast Afrezza works and more importantly, why it should immediately become the standard of care, industry leaders should finally start taking notice of the huge difference between Afrezza and all other options.
|
|
|
|
Post by dreamboatcruise on May 14, 2018 9:13:13 GMT -5
Once the STAT study results are released and Dr. Kendall can share with his peers how fast Afrezza works and more importantly, why it should immediately become the standard of care, industry leaders should finally start taking notice of the huge difference between Afrezza and all other options. Speed of action has been right there in the label since Fall. |
|
|
|
Post by mnholdem on May 14, 2018 10:04:10 GMT -5
The label has been here since last Fall but Dr. Kendall has not.
|
|
|
|
Post by akemp3000 on May 14, 2018 10:06:37 GMT -5
Once the STAT study results are released and Dr. Kendall can share with his peers how fast Afrezza works and more importantly, why it should immediately become the standard of care, industry leaders should finally start taking notice of the huge difference between Afrezza and all other options. Speed of action has been right there in the label since Fall. Agreed but unfortunately that's not yet broadly accepted knowledge. This should change moving forward. |
|
